Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.180 -0.180 (-7.63%)

Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 ↗

August 05, 2024

RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

August 05, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides ↗

June 28, 2024

Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC...

Via Benzinga

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 28, 2024

Via Benzinga

Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

June 28, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Rocket Pharmaceuticals ↗

November 07, 2023

Via Benzinga

These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains ↗

June 14, 2024

These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.

Via Talk Markets

Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy

May 29, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 10, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 ↗

May 06, 2024

RCKT stock results show that Rocket Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 06, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

April 02, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

March 26, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

February 26, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

February 13, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

7 Speculative Stocks to Double Your Money THIS Year ↗

January 22, 2024

Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.

Via InvestorPlace

Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

December 12, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Merit Medical Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

December 05, 2023

U.S. stock futures traded lower this morning, with the Dow Jones futures falling more than 40 points on Monday.

Via Benzinga

Topics Stocks

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

November 06, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗

November 02, 2023

On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78

Via Investor's Business Daily

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 19, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

October 02, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference

September 26, 2023

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals ↗

September 23, 2023

Rocket could launch its medicines sooner, but Intellia is aiming for larger markets.

Via The Motley Fool

Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully ↗

September 18, 2023

Its near-term risks are subtle but bigger than their flying stock price might indicate.

Via The Motley Fool

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗

September 15, 2023

Investors are on the hunt for undervalued, under followed and emerging stocks. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming.

Via Benzinga

Dow Turns Lower; KULR Technology Group Shares Plummet ↗

September 13, 2023

U.S. stocks traded mixed toward the end of trading, with the Dow Jones falling 100 points on Wednesday. The Dow traded down 0.29% to 34,545.66 while the NASDAQ rose 0.22% to 13,803.43. The S&P 500,...

Via Benzinga

Topics Stocks

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.